Evidence map›Paper›PMID 34278967›Full record

ArticleEmerging microbes & infections2021

Lentil lectin derived from

Wenbo Wang, Qianqian Li, Jiajing Wu, Yu Hu, Gang Wu, Chuanfei Yu, Kangwei Xu, Xumei Liu, Qihui Wang, Weijin Huang and 2 more

Open access · goldAbstract read
In one paragraph

Article in Emerging microbes & infections, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 24 papers.

0numbers the graph read from it
0cells of the map it votes in
24citing papers in PubMed
2.8field-weighted citation impact, top 8% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

24 citing papers in PubMed, 49 citations in OpenAlex.

  1. Article
  2. Article
  3. Review
  4. Article
  5. Article
  6. Article
  7. Article
  8. Review
  9. Cyanovirin-N Binding toBiochemistry · 2024
    Article
  10. Review
  11. Review
  12. Article
  13. Review
  14. Review
  15. Article
  16. Article
  17. Review
  18. Review
  19. Lectins and lectibodies: potential promising antiviral agents.Cellular & molecular biology letters · 2022
    Review
  20. Plant lectins as prospective antiviral biomolecules in the search for COVID-19 eradication strategies.Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie · 2022
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 6 institutions in 2 countries.

Wenbo WangDivision of Monoclonal Antibody Products, National Institutes for Food and Drug Control (NIFDC), Beijing, People's Republic of China.
Qianqian LiDivision of HIV/AIDS and Sex-Transmitted Virus Vaccines, National Institutes for Food and Drug Control (NIFDC), Beijing, People's Republic of China.
Jiajing WuDivision of HIV/AIDS and Sex-Transmitted Virus Vaccines, National Institutes for Food and Drug Control (NIFDC), Beijing, People's Republic of China.
Yu HuCAS Key Laboratory of Pathogenic Microbiology and Immunology, Institute of Microbiology, Chinese Academy of Sciences (CAS), Beijing, People's Republic of China.
Gang WuDivision of Monoclonal Antibody Products, National Institutes for Food and Drug Control (NIFDC), Beijing, People's Republic of China.
Chuanfei YuDivision of Monoclonal Antibody Products, National Institutes for Food and Drug Control (NIFDC), Beijing, People's Republic of China.
Kangwei XuDivision of Respiratory Virus Vaccines, National Institutes for Food and Drug Control (NIFDC), Beijing, People's Republic of China.
Xumei LiuDivision of Monoclonal Antibody Products, National Institutes for Food and Drug Control (NIFDC), Beijing, People's Republic of China.
Qihui WangCAS Key Laboratory of Pathogenic Microbiology and Immunology, Institute of Microbiology, Chinese Academy of Sciences (CAS), Beijing, People's Republic of China.ORCID https://orcid.org/0000-0003-3768-0401
Weijin HuangDivision of HIV/AIDS and Sex-Transmitted Virus Vaccines, National Institutes for Food and Drug Control (NIFDC), Beijing, People's Republic of China.
Lan WangDivision of Monoclonal Antibody Products, National Institutes for Food and Drug Control (NIFDC), Beijing, People's Republic of China.
Youchun WangDivision of HIV/AIDS and Sex-Transmitted Virus Vaccines, National Institutes for Food and Drug Control (NIFDC), Beijing, People's Republic of China.
National Institutes for Food and Drug Control · CNChinese Academy of Medical Sciences & Peking Union Medical College · CNChinese Academy of Sciences · CNUniversity of Science and Technology of China · CNWuhan Institute of Bioengineering · CNYantai University · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The spike (S) protein of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) mutated continuously and newly emerging variants escape from antibody-mediated neutralization raised great concern. S protein is heavily glycosylated and the glycosylation sites are relatively conserved, thus glycans on S protein surface could be a target for the development of anti-SARS-CoV-2 strategies against variants. Here, we collected 12 plant-derived lectins with different carbohydrate specificity and evaluated their anti-SARS-CoV-2 activity against mutant strains and epidemic variants using a pseudovirus-based neutralization assay. The

Indexed as

AnimalsAntiviral AgentsHumansLens PlantMiceMice, Inbred BALB CPlant ExtractsPlant LectinsSARS-CoV-2SeedsAntiviral Agentslentil lectinPlant ExtractsPlant Lectinsantiviral lectincarbohydrate-binding proteinN-linked glycosylationpseudovirusSARS-CoV-2

Identifiers

PMID34278967
PMCPMC8330776
OpenAlexW3183417813

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.